Pegvorhyaluronidase alfa

DB14912InvestigationalProtein Based Therapies

Pegvorhyaluronidase alfa is under investigation in clinical trial NCT02241187 (Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection).

Mechanism: Pharmacologically active on Hyaluronan
Curator reviewed
Also known as: HUMAN HYALURONIDASE PH-20 (HYALURONOGLUCOSAMINIDASE PH-20, SPERM ADHESION MOLECULE 1, EC 3.2.1.35) PRECURSOR-(36-482)-PEPTIDE (MATURE (1-447)-PEPTIDE), PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, GLYCOFORM ALFA, SUBSTITUTED ON N6 OF AN AVERAGE OF 4 TO · PEGylated recombinant human hyaluronidase PH20 · POLY(OXY-1,2-ETHANEDIYL), .ALPHA.-(3-CARBOXYPROPYL)-.OMEGA.-METHOXY-, AMIDE WITH HYALURONOGLUCOSAMINIDASE (HUMAN ISOENZYME PH20)
Code names: PEGPH-20

Resolves to

Compound

UNIIP01I4980ZSCAS1620390-06-8

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

18Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which companies are running trials of Pegvorhyaluronidase alfa, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account